Vincerx Pharma (NASDAQ:VINC) Shares Scheduled to Reverse Split on Tuesday, January 28th

Vincerx Pharma, Inc. (NASDAQ:VINC) shares are scheduled to reverse split on the morning of Tuesday, January 28th. The 1-20 reverse split was announced on Thursday, January 23rd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 27th.

Vincerx Pharma Trading Down 19.4 %

Shares of Vincerx Pharma stock traded down $0.03 during mid-day trading on Friday, hitting $0.10. 7,380,350 shares of the stock were exchanged, compared to its average volume of 4,778,677. The stock has a market capitalization of $3.50 million, a price-to-earnings ratio of -0.10 and a beta of 1.48. Vincerx Pharma has a twelve month low of $0.10 and a twelve month high of $9.37. The company has a 50-day simple moving average of $0.22 and a 200 day simple moving average of $0.46.

Wall Street Analyst Weigh In

Separately, Leerink Partners decreased their target price on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Institutional Trading of Vincerx Pharma

A hedge fund recently bought a new stake in Vincerx Pharma stock. Armistice Capital LLC bought a new position in Vincerx Pharma, Inc. (NASDAQ:VINC) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,988,000 shares of the company’s stock, valued at approximately $1,610,000. Armistice Capital LLC owned about 6.70% of Vincerx Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 44.02% of the company’s stock.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.